Lv1
28 积分 2026-07-08 加入
The battle of “nano” paclitaxel
26天前
已完结
Emerging degrader technologies engaging lysosomal pathways
2个月前
已完结
Critical assessment of LC3/GABARAP ligands used for degrader development and ligandability of LC3/GABARAP binding pockets
3个月前
已完结
Development of Degraders of Cyclin-Dependent Kinases 4 and 6 Based on Rational Drug Design
3个月前
已完结
Development of Dual and Selective Degraders of Cyclin‐Dependent Kinases 4 and 6
3个月前
已完结
PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies
3个月前
已完结
Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer
3个月前
已完结
MKRN2-Mediated Degradation of IGF2BP3 Suppresses MYC and Enhances CDK4/6 Inhibitor Sensitivity in Bladder Cancer
3个月前
已完结
Developing Orally Active Estrogen Receptor Degraders by Conjugation of Boronic Tamoxifen and Cereblon Ligands
3个月前
已完结
CDK4/6-targeted therapy: From clinical inhibitors to emerging strategies to overcome resistance
3个月前
已完结
皖公网安备34019202002308
